Press Release: New Novartis data further support -2-

Novartis

104.50 EUR 0.00%

• Charts
• News
• Analysen

Kaufen Verkaufen

4. Guthrie E. Multiple sclerosis: A primer and update. Adv Studies Pharm.

2007;4(11):313-317.

5. Portaccio E, Magyari M, Kubala Havrdova E, et al. Multiple sclerosis:

emerging epidemiological trends and redefining the clinical course.

Lancet Reg. Health Eur. 2024;44:100977.

6. National Multiple Sclerosis Society. Types of MS. Available from:

https://www.nationalmssociety.org/understanding-ms/what-is-ms/types-of-ms

Accessed August 13, 2025.

7. Kesimpta. Prescribing Information. Novartis Pharmaceuticals Corporation

East Hanover. 2024.

https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf

Accessed September 12, 2025.

8. Kesimpta. Summary of Product Characteristics. Novartis Ireland Limited.

February 2025.

https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information_en.pdf

Accessed August 20, 2025.

9. Hauser SL, Kappos L, Bar-Or A, et al. The Development of Ofatumumab, a

Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing

Multiple Sclerosis Treatment. Neurol Ther. 2023;12(5):1491-1515.

10. Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with

subcutaneous administration of ofatumumab in relapsing multiple

sclerosis: results from the APLIOS bioequivalence study. Poster

presentation at Americas Committee for Treatment and Research in Multiple

Sclerosis (ACTRIMS) Annual Forum; February 27--29, 2020; West Palm Beach,

FL, US.

11. Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20

therapy effectively depletes B-cells and ameliorates CNS autoimmunity.

Poster presentation at: the European Committee for Treatment and Research

in Multiple Sclerosis (ECTRIMS) Annual Meeting 2016; September 14--17,

2016; London, UK.

12. Genmab. Press Release: Genmab announces completion of agreement to

transfer remaining ofatumumab rights. December 21, 2015. Available from:

https://ir.genmab.com/static-files/9d491b72-bb0b-4e46-a792-dee6c29aaf7d

Accessed August 13, 2025.

13. Novartis. Data on file.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

September 24, 2025 02:30 ET (06:30 GMT)